ClinicalTrials.gg
RecruitingNCT03910738TOTEM-RRMSUpdated Jun 29, 2025

TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

A Phase 2 interventional study of Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection and Placebo 4 mL Solution for Injection in Multiple Sclerosis, Relapsing-Remitting, sponsored by University Hospital, Strasbourg, France. Recruiting at 5 sites in France. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by University Hospital, Strasbourg, France · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2019; still recruiting 7 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France — 9 open to participants now, 14 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · France.

Planned enrollment
62nd of 70
40 · median 154
Started
2019
with 5 others
Phase 2
12 of 82
2 open now
Primary completion
2027-12
later than 9 of 13 live
Registered
59th of 82
by date
Lead sponsor
4 of 82
University Hospital, Strasbourg, France

Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, this one is the 62nd largest by planned enrollment of the 70 interventional ones that give a count, is one of 6 that started in 2019, is one of 12 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 59th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

9 of the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, or all of them as a file.
02

Study summary

Centra nervous system (CNF) damage in multiple sclerosis (MS), are mainly attributed to myelin destruction, axonal abnormalities and subsequent degeneration, and are responsible for serious deficiencies. Current therapies are focused on the treatment of inflammation with several types of anti-inflammatory agents. However, there is an urgent need for innovative therapies promoting neuroregeneration and particularly myelin repair.

It has been demonstrated that testosterone can act through neural androgen receptors to promote proliferation and differentiation of oligodendrocyte precursors into mature oligodendrocytes in a cuprizone-induced animal model of demyelination. The rare clinical trials on testosterone are mainly exploratory. Here, we sought to demonstrate an effect of testosterone supplementation in testosterone-deficient patients in a multicenter, randomized, parallel-group, double-blind, placebo-controlled phase 2 trial.

The main objective will be to determine the neuroprotective and remyelinating effects of testosterone using tensor diffusion imaging techniques and thalamic atrophy analyzes.

As secondary objectives, we would like to study the impact of testosterone supplementation on other conventional and unconventional MRI parameters and on clinical outcomes (cognition, fatigue, quality of life, impact on work / activity and anxiety / depression).

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Neuroprotection
  • Remyelination
  • Relapsing Remitting Multiple sclerosis
  • Testosterone undecanoate
  • Diffusion tensor Imaging
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man between 18 and 55 years
  • Patient affiliated to a social health insurance plan
  • Patient able to understand the objectives and risks related to the research and able to comply with the requirements of the protocol throughout the duration of the study
  • Patient having been informed of the results of the prior medical examination
  • Patient having signed an
  • Confirmed and documented diagnosis of MS, as defined by the revised McDonald criteria,
  • Patient who have been receiving one of the following disease modifying therapies for at least one year prior to randomization: natalizumab , fingolimod, ponesimod, ocrelizumab, or ofatumumab, in accordance with their prescribing information. Switching from one molecule to another during the previous year is also permitted, provided that the switch was motivated by a non-neurological reason (relapse, MRI activity). Patients receiving ocrelizumab within 6 to 9 months are eligible, provided they have received full-dose ocrelizumab for at least 2 years.
  • Biological hypogonadism defined by serum total testosterone levels below 20 nmol / L (checked by blood sampling during the screening visit)
  • For patients under natalizumab : Negative status for JC virus or JC virus synthesis index ≤ 1.5 (checked by blood sampling at the inclusion visit)
  • No relapses in the year prior to inclusion
  • Disability status during the selection visit with an EDSS score of 0 to 7 (verified by questionnaire during the inclusion visit)
  • Stable neurological state in the month preceding randomization

Exclusion criteria

Exclusion Criteria:

  • Patients with progressive MS (primary or secondary)
  • Patients with hypogonadism with clinical symptoms and treated with androgens
  • Patients with PSA (prostate specific antigen)> 2.5 ng / ml (for an age less than 49 years old) or > 3.5 ng / ml (for age ≥ 50 years) (checked by a blood test at the inclusion visit)
  • Patients with a hematocrit level > 54% (checked by blood sampling during the inclusion visit)
  • Patients refusing or unable to undergo an MRI
  • Patients with any other disease other than MS that may contribute to neurological symptoms and signs or affect their evaluation
  • Patients with neurological signs compatible with progressive multifocal leukoencephalopathy (PML) or confirmed leukoencephalopathy
  • Patients diagnosed with untreated sleep apnea
  • Patients with or having had cancer or tumors of the liver, heart, kidney, prostate or mammary gland
  • Patients with cardiovascular, renal, hepatic, hematological, gastrointestinal, pulmonary, uncontrolled diseases
  • Patients wishing to procreate during the study period
  • Patients with chronic infectious disease
  • Patients with organic or psychiatric disease compromise their ability to understand the information given and to follow the protocol
  • Patients with a history of to treatment or any of the , or drugs of similar chemical classes
  • Patients who used experimental drugs and / or who participated in clinical drug trials in the 6 months prior to selection
  • Patient in exclusion period (determined by previous study or in progress)
  • Impossibility of giving information to the patient (subject in emergency situation, difficulties in understanding the subject or other)
  • Incapacitated subject (subject to a legal protection measure: safeguard of justice, curatorship, guardianship, future protection mandate, family habilitation)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Testosterone treatment (Nebido®)

    "Treatment/Nebido®" arm: in this experimental arm, each patient will be injected intramuscularly with 1000 mg / 4 ml of testosterone undecanoate (Nebido®). Treatment will be injected at baseline, week 6, 18, 30, 42 and 54

    Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection · Procedure: MRI · Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities · Behavioral: Assessment of disability

  • Placebo comparator
    Placebo

    "Placebo" arm: In this arm, each patient will be injected intramuscularly with 4 ml of placebo solution. Placebo will be injected at baseline, week 6, 18, 30, 42 and 54

    Drug: Placebo 4 mL Solution for Injection · Procedure: MRI · Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities · Behavioral: Assessment of disability

Interventions

  • DrugNebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection

    Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)

  • DrugPlacebo 4 mL Solution for Injection

    Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)

  • ProcedureMRI

    Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)

  • BehavioralAssessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities

    BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)

  • BehavioralAssessment of disability

    EDSS (Baseline, week 30 and 66)

06

What researchers measure

Primary outcomes

  1. Change on MRI binary criterion combining thalamic atrophy and modification in transverse diffusivity of lesions

    The primary endpoint is a binary criterion comparing the success rate in each treatment group, defined by thalamic atrophy lower than 0.5% and modification in transverse diffusivity of lesions lower than 0.5% per year compared between baseline and week 66 in each group.

    Time frame: At baseline, week 30 and week 66 (end of study)

Secondary outcomes

  1. Evolution of the number of T1 hypointense lesions as detected by conventional MRI

    Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  2. Evolution of the volume of T1 hypointense lesions as detected by conventional MRIconventional MRI

    Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  3. Evolution of the number of new or enlarged T2 lesions as detected by conventional MRI

    Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  4. Evolution of the volume of new or enlarged T2 lesions as detected by conventional MRI

    Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  5. Evolution of the total volume of hyper-intensity FLAIR lesion as detected by conventional MRI

    Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  6. Evolution of diffusion tensor imaging (NODDI) as detected by unconventional MRI

    Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  7. Evolution of quantitative magnetization transfer imaging (MPF) as detected by unconventional MRI

    Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  8. Evolution of cognitive performance as measured by Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

    BICAMS is a composite cognitive assessment tool comprising of the three components: Symbol Digit Modalities Test (SDMT), California Verbal Learning Test-II (CVLT-II) and Brief visuospatial memory test- Revised (BVMT-R). Efficacy will be assessed by comparing the composite score between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  9. Changes in quality of life as measured by the SF-36 questionnaire

    SF-36 questionnaire is a 36-item Short Form survey designed to examine the perceived health status measured in eight health concepts. Answers to each question are scored and summed to produce raw scale scores for each health concept. Efficacy will be assessed by comparing scores between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  10. Changes in quality of life related to health as measured by the EQ-5D-3L (European Quality of Life in 3 Dimensions) questionnaire.

    EQ-5D-3L is a standardized instrument used as a measure of health outcome. It is a health questionnaire that consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. Efficacy will be assessed by comparing the composite scores between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  11. Changes in work productivity and daily activities due to MS, as assessed by the WPAI:MS questionnaire (Work Productivity and Activity Impairment in MS).

    WPAI questionnaire measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteeism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Efficacy will be assessed by comparing score between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  12. Changes in fatigue, measured by the Multidimensional Fatigue Impact Scale (MFIS)

    MFIS is a 21-item questionnaire that assesses overall self-reported fatigue. Subjects rate agreement with a series of statements on a scale of 0 (rarely) to 4 (almost always), in context of their fatigue over the preceding four weeks. Total possible score of 84. Individuals with an MFIS score of \> 38 are considered to experience moderate to severe "fatigue". Efficacy will be assessed by comparing score between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  13. Changes in anxiety and depression as measured by the Hospital assessment for Anxiety and Depression Scale (HADS) questionnaire

    HADS is a 14-item self-rating scale that assesses anxiety and depression. Each question is scored on a scale ranging from 0 to 3. Responses are summed to provide separate scores for anxiety and depression that range from 0 to 21. For each corresponding subscale, a total score of 0-7 equals normal, 8-10 equals borderline case, and 11-21 equals case. Efficacy will be assessed by comparing score between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  14. Evolution of disability measured MS specific Expanded Disability Status scale (EDSS)

    EDSS measures disability status on a scale ranging from 0 to 10, in eight functional system scale: motor, sensory, cerebellar, brain stem, visual, mental, sphincter and other systems. The EDSS is formed on the score in each functional system; higher scores indicating more disability (0 = normal examination and 10= death from MS). Efficacy will be assessed by comparing score between the 2 groups and in each group between baseline, week 30 and week 66.

    Time frame: At baseline, week 30 and week 66 (end of study)

  15. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Safety of treatment will be followed by the number and type of adverse or severe adverse events (AE/SAE) throughout the protocol (from baseline to week 66)

    Time frame: From Visit 0/baseline to end of study visit (66 weeks)

07

Study locations

5 of 5 sites recruiting
08

References and documents

Publications

  • Metzger-Peter K, Kremer LD, Edan G, Loureiro De Sousa P, Lamy J, Bagnard D, Mensah-Nyagan AG, Tricard T, Mathey G, Debouverie M, Berger E, Kerbrat A, Meyer N, De Seze J, Collongues N. The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2020 Jun 29;21(1):591. doi: 10.1186/s13063-020-04517-6. PubMed 32600454 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Dec 2027, 98 months after the start.

Of 25 phase 2 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 98 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2019
First posted
Apr 10, 2019
StartActual
Oct 29, 2019
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03910738
Collaborators
Bayer, Fédération Hospitalo-Universitaire NEUROGENYCS, Grünenthal GmbH
Responsible party
Sponsor
First posted
Apr 10, 2019
Start date
Oct 29, 2019
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 29, 2025

Study contacts

Laurent D KREMER, MD
Contact
laurentdaniel.kremer@chru-strasbourg.fr
+333 88 12 87 33
Nicolas COLLONGUES, MD
Contact
nicolas.collongues@chru-strasbourg.fr
+333 88 12 87 33
Laurent D KREMER, MD
principal investigator · CHU Strasbourg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion